September 07, 2008
Home
About
Submit Press Release
PR Firms
Editors/Journalists
Search Archives
 
News Releases by Category  
News by Country  
News by MSA  
All News for Today  
Browse News by Day  
News by Trackbacks  
All Press Releases for September 17, 2004 Subscribe to this News Feed  
 

MycoLogics, Inc. Expands MycoDetect Suite of Antifungal Compound Identification Screening Services

MycoLogics, Inc., today announced the availability of MycoDetect, a comprehensive screening service used to identify active antifungal compounds.

DENVER, CO (PRWEB) September 17, 2004 -- MycoLogics, Inc., an innovative biotechnology company specializing in the development of novel drugs and vaccines for the prevention and treatment of infectious diseases, today announced the availability of MycoDetect, a comprehensive screening service used to identify active antifungal compounds.

The unique problems posed by the need for novel antifungal drugs call for the exploration of new biological sources of compounds. Now previously unexplored sources of potential bioreactive compounds may be screened for antifungal activity utilizing the new MycoDetect system of whole-cell and in vitro enzyme assays. The applied preeminent expertise of MycoLogics of identifying fungal cell wall targets combined with unique libraries of candidates will allow MycoDetect to quickly reveal lead compound strategies. The MycoDetect identification system has successfully screened libraries for antifungal activity from such diverse sources as thermal waters, microbial mats, fumaroles, microalgae and cyanobacteria. The availability of MycoDetect permits the rapid and cost-effective screening of extracts and compounds.

Contact MycoLogics to learn more about MycoDetect

About MycoLogics, Inc.
MycoLogics, Inc. is an innovative biotechnology company specializing in the development of novel antifungal drugs and therapeutic and prophylactic vaccines against human fungal and parasitic pathogens, the discovery and isolation of novel antifungal compounds for therapeutic use, and the development of novel high throughput assays that target components of fungal cell walls. MycoLogics, Inc. is headquartered in Aurora, CO at the Fitzsimmons Colorado Bioscience Park. For more information please visit www.mycologics.com.

CONTACT INFORMATION:
Dr. Claude P. Selitrennikoff, Ph.D.
President and CEO
MycoLogics, Inc.
Colorado Bioscience Park
12635 East Montview Blvd., Suite 131
Aurora, CO 80010
Tel: (720) 859-4190
Fax: (303) 724-0861
claude.selitrennikoff@uchsc.edu

###


See the original story at: http://www.prweb.com/releases/2004/09/prweb158820.htm
Other Releases by this Member
Email this story to a colleague
Printer Friendly Version
Bookmark with del.icio.us
Bookmark with Y!MyWeb
Submit to Digg
Adam Rubenstein
RNA VENTURES, LLC
303-902-4413
Email us Here

There are no multimedia files attached to this release. If this is your release you may add images or other multimedia files through your login.

If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2007, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright